Vitamin D derivatives inhibit mesenchymal transition of mesothelial cells and mitigate peritoneal dissemination of ovarian cancer
- PMID: 39964447
- DOI: 10.1007/s00795-025-00424-4
Vitamin D derivatives inhibit mesenchymal transition of mesothelial cells and mitigate peritoneal dissemination of ovarian cancer
Abstract
Ovarian cancer (OvCa) is a leading cause of gynecological cancer-related mortality, primarily due to peritoneal dissemination, which facilitates metastasis in the abdominal cavity. This study explored the potential of vitamin D and its synthetic derivatives in mitigating peritoneal dissemination by modulating the behavior of mesothelial cells (MCs). Vitamin D, through its receptor (VDR), is known to influence cancer progression, and our findings demonstrate that vitamin D derivatives can inhibit mesenchymal transition of MCs induced by TGF-β1, a key driver of peritoneal dissemination. This study used patient-derived primary MCs and in vivo mouse model to assess the effects of vitamin D derivatives on cell morphology, gene expression, and OvCa cell adhesion. Two vitamin D derivatives, VDR agonist, showed significant efficacy in maintaining epithelial-like MC morphology, reducing TGF-β1-induced changes, and inhibiting OvCa cell adhesion to the peritoneum, similar to calcitriol. Conversely, the VDR antagonist derivative induced MC apoptosis, highlighting the essential role of vitamin D in MC survival. These findings suggest that vitamin D derivatives could serve as promising therapeutic agents for OvCa by preserving peritoneal homeostasis and preventing metastasis. Further research is required to explore a broader range of derivatives and their underlying molecular mechanisms.
Keywords: Mesenchymal transition; Mesothelial cells; Ovarian cancer; Peritoneal dissemination; Vitamin D.
© 2025. The Author(s) under exclusive licence to The Japanese Society for Clinical Molecular Morphology.
Conflict of interest statement
Declarations. Conflict of interest: The authors have declared that no conflict of interest exists.
References
-
- Siegel RL, Miller KD, Wagle NS, Jemal A (2023) (2023) Cancer statistics. CA Cancer J Clin 73(1):17–48. https://doi.org/10.3322/caac.21763 - DOI - PubMed
-
- Lengyel E (2010) Ovarian cancer development and metastasis. Am J Pathol Internet Am Soc Investigative Pathol 177(3):1053–1064
-
- Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E et al (2015) Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial. Lancet Oncol 16(8):928–936. https://doi.org/10.1016/S1470-2045(15)00086-8 - DOI - PubMed - PMC
-
- González-Martín A, Pothuri B, Vergote I, DePont CR, Graybill W, Mirza MR et al (2019) Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 381(25):2391–2402. https://doi.org/10.1056/NEJMoa1910962 - DOI - PubMed
-
- Mogi K, Yoshihara M, Iyoshi S, Kitami K, Uno K, Tano S et al (2021) Ovarian cancer-associated mesothelial cells: transdifferentiation to minions of cancer and orchestrate developing peritoneal dissemination. Cancers (Basel) 13(6):1352. https://doi.org/10.3390/cancers13061352 - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical